Virtual Posters

Big Data

PO-001  ARNTL2 is a hypoxia-responsive master regulator of PDAC malignancy. Alvaro Curiel-Garcia\textsuperscript{1}, Carlo H. Maurer\textsuperscript{2}, Pasquale Laise\textsuperscript{3}, Irina Sagalovskiy\textsuperscript{4}, John A. Chabot\textsuperscript{4}, Gulam A. Manji\textsuperscript{4}, Alina Iuga\textsuperscript{5}, Kristen Johnson\textsuperscript{6}, Andrea Califano\textsuperscript{4}, Kenneth P. Olive\textsuperscript{4}. 1Columbia University, New York, NY, 2Technische Universität München, Munich, Germany, 3Darwin Therapeutics, New York, NY, 4Columbia University, New York, NY, 5University of North Carolina, Chapel Hill, NC, 6University of New Hampshire, Manchester, NH.

PO-002  Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort. James M. Davison\textsuperscript{1}, Greg Mayhew\textsuperscript{1}, Kirk Beebe\textsuperscript{1}, Joel R. Eisner\textsuperscript{1}, Dennis Ladnier\textsuperscript{2}, Eric A. Collijson\textsuperscript{3}, Lynn M. Matrisian\textsuperscript{2}. 1GeneCentric Therapeutics, Inc, Durham, NC, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

PO-003  Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status. Jasmeet Kaur\textsuperscript{1}, Tanveer Mir\textsuperscript{2}, Paramveer Singh\textsuperscript{3}, Judie Goodman\textsuperscript{1}. 1Saint Joseph Mercy Oakland Hospital, PONTIAC, MI, 2Wayne State University, Detroit, MI, 3Karmanos Cancer Center, Detroit, MI.

PO-004  Basal-like, Classical A, and Classical B subtypes of pancreatic cancer show distinct immuno-suppressive molecular profiles. Emily L. LaPlante\textsuperscript{1}, Dongliang Liu\textsuperscript{1}, Aleksandar Milosavljevic\textsuperscript{1}, Qizhi Yao\textsuperscript{1}. 1Baylor College of Medicine, Houston, TX.

PO-005  Proteome profiling of Pancreatic Ductal Adenocarcinoma (PDAC) primary tumors in Caucasian, African Americans and Latinx patients. Henry C. H. Law\textsuperscript{1}, Andrea N. Riner\textsuperscript{2}, Jose G. Trevino\textsuperscript{3}, Nicholas T. Woods\textsuperscript{1}. 1University of Nebraska Medical Center, Omaha, NE, 2University of Florida, Gainesville, FL, 3Virginia Commonwealth University, Richmond, VA.

Diagnostics, Early Detection, and Imaging

PO-006  CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Chi Hin Wong\textsuperscript{1}, Ut Kei Lou\textsuperscript{1}, Frederic Khe-Cheong Fung\textsuperscript{1}, Joanna H. M. Tong\textsuperscript{2}, Ka-Fai To\textsuperscript{2}, Stephen Lam Chan\textsuperscript{3}, Yangchao Chen\textsuperscript{4}. 1School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 3Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 4School of Biomedical Sciences, Faculty of Medicine, and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong.
PO-007  Plasma-based detection of pancreatic cancer: A multiomics approach. Teng-Kuei Hsu1, Tzu-Yu Liu1, Billie Gould1, Christine Decapite2, Amer Zureikat2, Alessandro Paniccia3, Eric Ariazi1, Marvin Bertin1, Richard Bourgon1, Kaitlyn Coil1, Hayley Donnella1, Adam Drake1, Julie M. Granka1, Preet Kaur1, Maggie C. Louie1, Amit Pasupathy1, Ofer Shapira1, Peter Ulz1, Chun Yang1, C. Jimmy Lin1, Randall Brand2. 1Freenome Holdings Inc., South San Francisco, CA, 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 3Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

PO-008  Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis. Laura E. Kane1, Gregory S. Mellotte2, Eimear Mylod1, Rebecca O'Brien1, Fiona O'Connell1, Khanh Nguyen3, Croí E. Buckley1, Jennifer Arlow3, David Mockler1, Aidan D. Meade3, Barbara M. Ryan2, Stephen G. Maher1. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3Technological University Dublin, Dublin, Ireland.

PO-009  Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk. Laura E. Kane1, Gregory S. Mellotte2, Simone Marcone1, Barbara M. Ryan2, Stephen G. Maher1. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland.

PO-010  Detection of early tissue changes on historical CT scans in the regions of the pancreas gland that subsequently develop adenocarcinoma using quantitative textural analysis and fat fraction analysis. Ronald L. Korn1, Daniel D. Von Hoff2, Andre Burkett1, Dominic Zygadlo1, Taylor Brodie3, Kathleen Panak1, Sweta Rajan1, Derek Cridebring2, Michael J. Demeure3. 1Imaging Endpoints, Scottsdale, AZ, 2Translational Genomics Research Institute, Phoenix, AZ, 3Hoag Hospital, Newport Beach, CA.

PO-011  The spectrum of pathogenic germline variants in pancreatic cancer patients with multiple primary tumors. Valentyna Kryklyva1, Lodewijk A.A. Brosens2, Marjolijn J.L. Ligteneberg1, Iris D. Nagtegaal1. 1Radboud university medical center, Nijmegen, Netherlands, 2University Medical Center Utrecht, Utrecht, Netherlands.

PO-012  The concept of artificial intelligence against pancreatic cancer. Subash Kumar1. 1DMI Lochbridge, Elkridge, MD.

PO-013  Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) Study. Nicolette J. Rodriguez1, Constance S. Furniss2, Matthew B. Yurgelun3, Chinedu Ukaegbu4, Pamela E. Constantinou5, Alison N. Schwartz4, Jill Stopfer4, Meghan Underhill-Blazey6, Barbara Kenner7, Scott Nelson8, Sydney Okumura9, Sherman Law9, Alicia Y. Zhou9, Tara B. Coffin10, Hajime Uno2, Allyson Ocean11, Florencia McAllister5, Andrew M. Lowy12, Scott M. Lippman12, Alison P. Klein13, Lisa Madlensky12, Gloria M. Petersen14, Judy E. Garber1, Michael G. Goggins13, Anirban Maitra5, Sapna Syngal3, 1Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard
PO-014  VISTA: VIusual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts. Luke Ternes1, Ge Huang1, Christian Lancialut1, Guillaume Thibault1, Rachelle Riggers2, Joe Gray2, John Muschler1, Young Hwan Chang1. 1Oregon Health and Science University, Portland, OR, 2Oregon Health and Science University, Portland, OR.

Early Phase Clinical Trials

PO-015  A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with previously untreated metastatic pancreatic cancer (MPC). Gayle S. Jameson1, Erkut H. Borazanci1, Daniel D. Von Hoff2, Joshua D. Rabinowitz3, Michael S. Gordon1, Sarah D. LeGrand1, Courtney Snyder1, Karen Ansaldo1, Denise J. Roe4, Haiyong Han2. 1HonorHealth, Scottsdale, AZ, 2Translational Genomics Research Institute (TGen), Phoenix, AZ, 3Princeton University, Princeton, NJ, 4University of Arizona Cancer Center, Tucson, AZ.

Immunotherapy

PO-016  Directed evolution generates novel oncolytic H-1 parvoviruses with improved therapeutic efficacy in virus-resistant pancreatic cancer cells. Pierre Garcin1, Monireh Kazemimanesh1, Hubert Lulka1, Nelson Dusetti2, Guillaume Labrousse1, Emilie Benuzzi1, Louis Buscail3, Pierre Cordelier1. 1Cancer Research Center of Toulouse, INSERM, Toulouse, France, 2Cancer Research Center of Marseilles, INSERM, Marseilles, France, 3Cancer Research Center of Toulouse, INSERM and Toulouse University Hospital, Toulouse, France.

PO-017  Application of oncolytic adenovirus to desmoplastic pancreatic cancer. Flora Hossain1, Fumihiro Higashino1. 1Hokkaido University, Sapporo, Japan.

PO-019  Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Bhalchandra Mirlekar¹, Yuliya Pylayeva-Gupta¹, ¹Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO-020  Heating up immune cold pancreatic adenocarcinoma with bioengineered immunotherapy remodels tumor microenvironment and prevents metastasis in vivo. Chanthirika Ragulan¹, Patrick Varun Lawrence¹, Hari PS¹, Krisha Desai¹, Jun Ishihara², Anguraj Sadanandam¹. ¹The Institute of Cancer Research, Sutton, United Kingdom, ²Imperial College London, London, United Kingdom.

Metabolism

PO-021  Targeting the mitochondrial pyruvate complex to alter metabolic programming in pancreatic cancer. Hassan A. Ali¹, Andrew Metcalfe², James T. Topham², Cassia S. Warren², Joanna M. Karasinska², David F. Schaeffer², Daniel J. Renouf³. ¹University of British Columbia, Vancouver, BC, Canada, ²Pancreas Centre BC, Vancouver, BC, Canada.

PO-022  Exploiting a redox bottleneck to combat drug tolerance in pancreatic cancer. Holly Brunton¹, Ludimila Cavalcante², David Sumptom¹, Francis Giles², Owen Sansom¹. ¹CRUK Beatson Institute, Glasgow, United Kingdom, ²Actuate Therapeutics, Fort Worth, TX.

PO-023  Impaired adipose anabolism drives fat wasting in pancreatic cancer cachexia. Katherine Pelz¹, Grace McCarthy¹, Heike Mendez¹, Samantha Z. Brown¹, Jonathan R. Brody¹, Aaron J. Grossberg¹. ¹Oregon Health & Science University, Portland, OR.

PO-024  Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. William A. Hall¹, Husain Y. Khan², Mandana Kamgar¹, Susan Tsai¹, Kathleen Christians¹, Douglas B. Evans¹, Philip Philip², Callisia Clarke¹, Ben George¹, Beth Erickson¹, Asfar S. Azmi². ¹Medical College of Wisconsin, Milwaukee, WI, ²Karmanos Cancer Institute, Wayne State University, Detroit, MI.


PO-026  CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma. Dandan Zheng¹, Xianxian Huang², Juanfei Peng¹, Yanyan Zhuang¹, Yuanhua Li³, Junchi Qu¹, Shineng Zhang¹, Fengting Huang¹. ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ²the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, ³Tungwah Hospital of Sun Yat-sen University, Dongguan, China.

PO-028 Pancreatic ductal adenocarcinoma is dependent on an unconventional pathway for polyamine synthesis. Min-Sik Lee1,2,3, Insia Naqvi1, Courtney Dennis4, Lucas Dailey4, Alireza Lorzadeh5, Tamara Zaytouni1, Ashley Adler1,3, Daniel S. Hitchcock4, Lin Lin1, Unmesh Jadhav5,6, Clary B. Clish4, and Nada Y. Kalaany1,2,3. 1Division of Endocrinology, Boston Children’s Hospital, Boston, MA, 2Department of Pediatrics, Harvard Medical School, Boston, 3Broad Institute of MIT and Harvard, Cambridge, MA, 4Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, 5Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 6Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

PO-029 Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Blanca Majem1, Insia Naqvi1, Courtney Dennis2, Lucas Dailey2, Clary B. Clish2, Nada Kalaany1. 1Boston Children’s Hospital, Harvard Medical School, Boston, MA, 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.

PO-030 No time to rest: Vulnerabilities associated with metabolic deprivation in pancreatic cancer cells. Yogev Sela1, Jinyang Li1, Shivahamy Maheswaran1, Robert Norgard1, Salina Yuan1, Maimon Hubbi1, Clementina Measanos1, Ian Blair1, Ophir Shalem1, Chi Van Dang2, Ben Stanger1. 1University of Pennsylvania, Philadelphia, PA, 2Wistar, Philadelphia, PA.

PO-031 Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA. Dilru Silva, Conan Kinsey, Martin McMahon. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

PO-032 Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Lifeng Yang, Joshua Rabinowitz. Princeton University, Princeton, NJ.

Microbiome

PO-033 Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. Amanda R. Decker1, Tetsuhiro Harimoto2, Steve A. Sastra1, Tal Danino2, Kenneth P. Olive1. 1Columbia University Medical Center, New York, NY, 2Columbia University, New York, NY.

Other

PO-034 CPSF3 inhibition halts pancreatic cancer cell proliferation by limiting core histone supplies. Abdulrahman A. Alahmari1, Carla Schwarz2, Emily Paterson2, Swati Venkat2, Arwen Tisdale2, Michael E. Feigin2. 1Roswell Park Comprehensive Cancer Center, Amherst, NY, 2Roswell Park Comprehensive Cancer Center, Buffalo, NY.
PO-035  Uncovering a myosin phosphatase regulator in pancreatic tumor cell mechanics and behavior. Shantel M. Angstadt, Qingfeng Zhu, Douglas N. Robinson, Elizabeth M. Jaffee, Robert A. Anders. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-036  LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects. Diana Restifo¹, Aditya Kulkarni², Caleb Schimke², Joseph McDermott², Umesh Kathad², Kishor Bhatia², Panna Sharma², Igor Astsaturov¹. ¹Fox Chase Cancer Center, Philadelphia, PA, ²Lantern Pharma, Dallas, TX.

PO-037  Development of an RGD CRISPR-modified Clostridium novyi NT Spores as an Intravenous Oncotherapy. Kaitlin M. Dailey¹, Krysten Vance², Kyle McAndrews³, Reed I. Jacobson⁴, Jandro Delgado⁴, Paige R. Johnson⁵, Taylor M. Woolery⁵, Megan Orr⁴, Jiha Kim⁷, Sanku Mallik⁵, Kenneth W. Bayles⁸, Michael A. Hollingsworth², Amanda E. Brooks⁹. ¹Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, ²Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, ³Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Biological Sciences, North Dakota State University, Fargo, ND, ⁵Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND, ⁶Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁷Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND and Department of Research and Scholarly Activity, Rocky Vista University, Ivins, UT, Fargo, ND.

PO-038  LAMC2: new player in stemness and tumor progression in pancreatic cancer. Donatella Delle Cave¹, Tea Teresa Iavazzo¹, Maria Mangini², Gennaro Andolfi¹, Teresa Pirozzi¹, Annalisa Di Domenico¹, Annachiara De Luca², Enza Lonardo¹. ¹Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’ (IGB), CNR, Naples, Italy, ²Institute of Biochemistry and Cellular Biology, National Research Council of Italy, Naples, Italy.

PO-039  Antiproliferative activity of inhibitors of RAD51, singly and in combination with chemotherapy drugs, against pancreatic cancer cell lines. Peter Ferguson¹, Mark D. Vincent¹, Yousef Najajreh², Brian Shilton³, Stephen Ritter³, Rima Al-awar⁴, Richard Marcellus⁴, Mohammed Mohammed⁴, Methvin Isaac⁵, James Koropatnick⁴. ¹London Health Sciences Centre, London, ON, Canada, ²Al Quds University, Jerusalem, Palestinian Territory, ³Western University, London, ON, Canada, ⁴Ontario Institute for Cancer Research, Toronto, ON, Canada.

PO-040  Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing. Jelena Grahovac¹, Marijana Pavlovic¹, Marija Ostojic¹, Kristina Zivic¹, Daniel Galun², Tatjana Srdic-Rajic¹. ¹Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, ²School of Medicine, University of Belgrade; First Surgical Clinic, Clinical
PO-041  Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells. Dmytro Grygoryev¹, Taelor Ekstrom¹, Jason M. Link², Rosalie C. Sears², Jungsun Kim¹. ¹Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland, OR, ²Oregon Health & Science University, Portland, OR.

PO-042  ANGPTL4 accelerates KRASG12D-induced acinar to ductal metaplasia and pancreatic carcinogenesis. Kyung Hee Jung¹, Young-Chan Youn¹, Soon-Sun Hong¹. ¹College of Medicine, Inha University, Incheon, Republic of Korea.

PO-043  Cytidine deaminase protects pancreatic cancer cells from replicative stress and drive response to DNA-targeting drugs. Audrey Lumeau¹, Nicolas Bery¹, Cyril Ribeyre², Samad Elkoutrari³, Guillaume Labrousse¹, Miguel Madrid-Mencia¹, Vera Pancaldi¹, Marie-Jeanne Pillaire¹, Valérie Bergoglio⁵, Nelson Dusseti², Jean-Sébastien Hoffmann⁶, Louis Buscail⁷, Malik Lutzmann², Pierre Cordelier¹. ¹Cancer Research Center of Toulouse, Toulouse, France, ²IGH Montpellier, Montpellier, France, ³Cancer Research Center of Marseille, Marseille, France, ⁴IPBS Toulouse, Toulouse, France, ⁵CBI Toulouse, Toulouse, France, ⁶IUCT Oncopole Toulouse, Toulouse, France, ⁷CHU Rangeuil Toulouse, Toulouse, France.


PO-046  The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: a prospective study of the PREOPANC-1 randomized controlled trial. Diba Latifi, Willem de Koning, Sai ping Lau, Frederiek Grevers, Coen van Dam, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-047  Optimizing the efficacy of 5-FU as a chemotherapeutic agent in advanced pancreatic ductal adenocarcinoma (PDAC) using MIAPaCa-2 and PANC-1 cells. Nkafu Bechem Ndemazie¹, Andriana Inkoom¹, Xue Y. Zhu¹, Edward Agyare¹. ¹Florida A&M University, Tallahassee, FL.

PO-048  A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer. Chun-Hao Pan¹, Robert Tseng¹, Simon J. Hogg², Gabriella Baraks¹, Cindy V. Leiton¹, Lucia Roa-Peña¹, Natalia Marchenko¹, Kenneth R. Shroyer¹, Luisa F. Escobar-Hoyos³. ¹Stony Brook University, Stony Brook, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Yale University, New Haven, CT.

PO-049  Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. Thao ND Pham¹, Christina Spaulding¹, Mario A. Shields¹.
PO-050  **Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).** Vincent J. Picozzi1, Anne-Marie Duliege2, Anirban Maitra3, Manuel Hidalgo4, Andrew Eugene Hendifar5, Gregory L. Beatty6, Sudheer Doss Doss2, Regina Deck2, Lynn M. Matrisian2, Julie Fleshman2, Diane M. Simeone7. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3University of Texas MD Anderson Cancer Center, Houston, TX, 4Weill Cornell Medicine, New York, NY, 5Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 6University of Pennsylvania, Philadelphia, PA, 7NYU Langone Health, New York, NY.

PO-051  **PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma.** Vincent J. Picozzi1, Teresa Macarulla2, Philip A. Philip3, Carlos R. Becerra4, Tomislav Dragovich5. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, 3Karmanos Cancer Institute, Detroit, MI, 4Baylor University Medical Center, Dallas, TX, 5Banner MD Anderson Cancer Center, Gilbert, AZ.

PO-052  **A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort.** Luca Pompella1*, Michela Falco2*, Carlo Caputo2*, Anna Grimaldi2, Giuseppe Tirino1, Severo Campione3, Francesca Sparano1, Maria Lucia Iacovino1, Chiara Carmen Miceli1, Carlo Molino4, Marco Montella5, Renato Franco5, Gennaro Galizia6, Giovanni Conzo7, Vincenzo Napolitano7, Annamaria Auricchio6, Francesca Cardella6, Fortunato Ciardiello1, Michele Caraglia2, Angela Lombardi2, Gabriella Misso7 and Ferdinando De Vita1*. 1Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Aversa, Italy, 2Department of Precision Medicine, Division of Molecular Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 3Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Naples, Italy, 4Division of Surgical Pathology, AORN "Antonio Cardarelli", Naples, Italy, 5Division of General Surgery 1, AORN "Antonio Cardarelli", Naples, Italy, 6Division of Surgical Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 7Department of Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, 8Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. * These authors contributed equally to this work.

PO-053  **Radiosensitization of pancreatic cancer through intracellular gold nanocluster biomineralization.** Aaron S. Schwartz-Duval1, Michael P. Kim1, Sunil Krishnan2, Konstantin V. Sokolov1. 1MD Anderson Cancer Center, Houston, TX, 2Mayo Clinic, Jacksonville, FL.
PO-054  A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP). Nebojsa Skorupan1, Mehwish I. Ahmad1, Seth M. Steinberg1, Jane B. Trepel1, Derek Cridebring2, Haiyong Han2, Daniel D. Von Hoff3, Christine Alewine1. 1CCR, Bethesda, MD, 2Translational Genomics Research Institute, Phoenix, AZ.

PO-055  Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. Susan Tsai1, Erkut Borazanci2, Margaret Gulley3, Naim Rashid3, Jason Merker3, Abdul H Khan1, Phillip Chisholm1, Bryan Hunt1, Tamara Giorgadze1, William Hall1, Mandana Kamgar1, Douglas B Evans1, Jen Jen Yeh3. 1Medical College of Wisconsin, Milwaukee, WI, 2Honor Health Medical Group, Scottsdale, AZ, 3University of North Carolina, Chapel Hill, NC.

PO-056  Insulin receptor signaling in pancreatic acinar cells contributes to pancreatic cancer development. Anni M.Y. Zhang, Jenny C.C. Yang, Twan J.J. de Winter, David F. Schaeffer, Janel L. Kopp, James D. Johnson. The University of British Columbia, Vancouver, BC, Canada.

PO-057  Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer. Bo Zhang, Fei Teng, Nengming Lin. Hangzhou First People's Hospital, Hangzhou, China.

Preclinical Models

PO-058  Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on pancreatic cancer cell line. Yogesh Bendale1, Padma Shastri2, Radha Poojari3, Nandinee Khot2, Surendra Nagare2, Avinash Kadam2. 1Rasayu Cancer Clinic, Pune, India, 2Rasayani Biologics Pvt. Ltd, Pune, India, 3Innovation Centre, Tata Chemicals Ltd., Pune, India.

PO-059  Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Juliennel L. Carstens1, Sujuan Yang1, Pedro Correa de Sampaio1, Xiaofeng Zheng1, Souptik Barua2, Kathleen M. McAndrews1, Arvind Rao3, Jared K. Burks1, Andrew D. Rhim1, Raghu Kalluri1. 1MD Anderson Cancer Center, Houston, TX, 2Rice University, Houston, TX, 3University of Michigan, Ann Arbor, MI.

PO-060  N-terminal RHAMM cooperates with dysfunctional p53 to accelerate the progression of pancreatic cancer. Anthony Lin1, Jennifer Feng1, Xiang Chen1, Dunrui Wang2, Megan Wong1, George Zhang1, Joseph Na1, Tianjian Zhang1, Zhengming Chen1, Yao-Tseng Chen1, Yi-Chieh Nancy Du1. 1Weill Cornell Medicine, New York, NY, 2National Institutes of Health, Bethesda, MD.

PO-061  Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma. Isabel A. English1, Patrick J. Worth1, Amy T. Farrell1, Brittany L. Allen-Petersen2, Vidhi Shah1, Courtney Betts1, Xiaoyan Wang1, Colin J Daniel1, Mary C. Thoma1, Lisa M. Coussens1, Ellen M. Langer1, Rosalie C. Sears3. 1Oregon Health &
PO-062  EUS-guided biopsy of pancreatic mass lesions for the development of patient-derived organoids in Puerto Rico. Andrea S. Flores Pérez¹, Janet Mendez Vega¹, Ana M. Reyes Ramos¹, Carlos Micames², Madeline Torres-Lugo¹, Maribella Domenech¹. ¹University of Puerto Rico - Mayagüez, Mayagüez, Puerto Rico, ²Hospital Bella Vista, Mayagüez, Puerto Rico.

PO-063  Functional interrogation of immune escape in neoantigen-expressing pancreatic cancer identifies a critical role for the CD155/TIGIT axis. William Freed-Pastor¹, Laurens Lambert¹, Zackery Ely¹, Nimisha Pattada¹, Arjun Bhutkar¹, Alex Jaeger¹, George Eng¹, Kim Mercer¹, William Hwang¹, Tyler Jacks¹. ¹MIT, Cambridge, MA.

PO-064  ONC212 stimulates cytotoxic T-cell killing, increases tumor-immune cell interactions, and promotes tumor regression in combination with TLY012 in a PDAC murine model. Kelsey E. Huntington¹, Anna Louie¹, Young Lee¹, Jared Mompoint¹, Isacco Ferrarini², Aakash Jhaveri³, Varun V. Prabhu⁴, Allen Melemed⁴, Seulki Lee⁵, Wafik S El-Deiry¹. ¹Brown University, Providence, RI, ²University of Verona, Verona, Italy, ³Sidney Kimmel Medical College, Philadelphia, PA, ⁴Chimerix, Durham, NC, ⁵D&D Pharmatech, Gaithersburg, MD.

PO-065  SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer. Ashley Jensen¹, Gabriela R. Rossi², Ruben Muñoz¹, Kimberly Brothers¹, Lewis Gruber³, Misty Gruber³, Haiyong Han¹. ¹Translational Genomics Research Institute, Phoenix, AZ, ²SIWA Therapeutics, Inc., Chicago, IL.

PO-066  High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models. Ya'an Kang, Rafał Zielinski, Roberto Cardenas Zuniga, Maria Poimenidou, Magdalena Remiszewski, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Izabela Fokt, Waldemar Priebe. UT MD Anderson Cancer Center, Houston, TX.

PO-067  A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. Hiroyuki Kato¹, Keisuke Tateishi¹, Keisuke Yamamoto¹, Dousuke Iwadate¹, Hiroaki Fujiwara², Takuma Nakatsuka¹, Koji Miyabayashi¹, Yotaro Kudo¹, Ijichi Hideaki¹, Kazuhiko Koike³, Mitsuhiro Fujishiro¹. ¹Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, ³Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.

PO-068  Cholesterol auxotrophy promotes the expansion of centroacinar cells giving rise to the basal subtype of pancreatic adenocarcinoma. Michael Kotliar¹, Aizhan Surumbayeva², Linara Gabitova², Suraj Peri³, Diana Restifo², Kathy Q. Cai³, Artem Barski³, Igor Astsaturov². ¹Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, ³Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA.
Facility, Fox Chase Cancer Center, Philadelphia, PA, 5Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

**PO-069** Modeling the tumor microenvironment using tissue engineering technologies. Rodrigo Curvello1, Verena Kast2, Daniela Loessner1, 1Monash University, Clayton, Australia, 2Max Bergmann Center of Biomaterials Dresden, Dresden, Germany.

**PO-070** Longitudinal precision oncology platform to identify chemotherapy-induced vulnerabilities in pancreatic cancer. Katja Peschke1, Hannah Jakubowski1, Arlett Schäfer1, Carlo Maurer1, Sebastian Lange1, Felix Orben1, Raquel Bernad1, Felix Harder1, Matthias Eiber1, Rupert Öllinger1, Melissa Schlitter1, Wilko Weichert1, Veit Phillip1, Christoph Schlag1, Roland Schmid1, Rickmer Braren1, Bo Kong2, Ekin Demir1, Helmut Friess1, Roland Rad1, Dieter Saur1, Günter Schneider1, Maximilian Reichert1. 1Technical University of Munich, Klinikum rechts der Isar, Munich, Germany, 2University of Ulm, Ulm, Germany.

**PO-071** Losartan enhances the radiosensitivity of pancreatic ductal adenocarcinoma. Guoliang Qiao, Yongtao Wang, Sojoodi Mozhdeh, Barrett Cole, Darshini Kuruppu1, Zenan Lin, Lanuti Michael, Kenneth Tanabe, Motaz Qadan. Massachusetts General Hospital, Boston, MA.

**PO-072** Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy. Sruthi Ravindranathan1, Passang Tenzin1, Jian Ming Li1, Rohan Dhamsania1, Michael Ware1, Mohammad Zaidi1, Shuhua Wang1, Jingru Zhu1, Maria Cardenas1, Yuan Liu1, Gaurav Joshi1, Sanjeev Gumber1, Brian Robinson1, Anish Sen-Majumdar2, Shanmuganathan Chandrakasan1, Haydn Kissick1, Alan Frey2, Susan Thomas3, Bassel El-Rayas1, Gregory Lesinski1, Edmund K. Waller1. 1Emory University, Atlanta, GA, 2Cambium Oncology, Atlanta, 3Georgia Institute of Technology, Atlanta.

**PO-073** Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice. Kiyoshi Saeki1, Wanglong Qiu1, Richard Friedman1, Carrie Shawber1, Jan Kitajewski2, Jianhua Hu1, Gloria H. Su1. 1Columbia University Irving Medical Center, New York, NY, 2University of Illinois Chicago, Chicago, IL.

**PO-074** Identification of C-MET receptor as a therapeutic target in patient-specific tumoroid models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors. Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman. Cellaria Inc., Wakefield, MA.

**PO-075** The elucidation of the role of Prrx1 for acinar to ductal metaplasia in response to acute injury of pancreas in the novel mouse models. Kensuke Suzuki1, Alina Li1, Jason R. Pitaresi1, Anna M. Chiarella1, Gizem Efe1, Kensuke Sugiura1, Rohit Chandwani2, Anil K. Rustgi1, 1Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 2Department of Surgery, Weill-Cornell Medical School, New York, NY.

PO-077  Establishment of a novel living biobank of patient-derived pancreatic cancer organoids with genomic and drug response characterization. Irene Y. Xie1, Laura Tamblyn2, Karen Ng2, Eugenia Flores-Figueroa2, Julie M. Wilson3, Gun Ho Jang3, Amy X. Zhang5, Stephanie Ramotar2, Anna Dodd2, Nikolina Radulovich2, Jennifer J. Knox2, Grainne M. O’Kane2, Steven Gallinger2, Faiyaz Notta2. 1University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Ontario Institute of Cancer Research, Toronto, ON, Canada.

PO-078  Identification of new drivers in PDAC early progression using engineered human primary pancreatic cells. Yi Xu1, Jun Liu1, Michael Hunter Nipper1, Han Xu2, Pei Wang1. 1The University of Texas Health San Antonio, San Antonio, TX, 2MD Anderson Cancer Center, Smithville, TX.

PO-079  Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer. Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. UNC Chapel Hill, Chapel Hill, NC.


Signaling

PO-081  Studying MYC's contribution to replication stress at the nuclear pore. Gabriel M. Cohn, Colin J. Daniel, Daniel F. Liefwalker, Rosalie C. Sears. Oregon Health & Science University, Portland, OR.

PO-082  Delineating the molecular basis of early dissemination of pancreatic cancer. Taelor Ekstrom1, Dmytro Grygoryev1, Terry Morgan2, Kenneth S Zaret3, Jungsun Kim4. 1Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, 2Cancer Early Detection Advanced Research Center, Department of Pathology, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR, 3Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Cancer Early Detection Advanced Research Center, Department of Molecular and Medical Genetics, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR.
PO-083  Rac1 is required for the maintenance of Kras\(^{G12D}\)-driven pancreatic ductal adenocarcinoma. Adrien Grimont\(^1\), John Nguyen\(^1\), John Erby Wilkinson\(^2\), Paul Zumbo\(^1\), Laura Martin\(^1\), Steven D. Leach\(^3\), Rohit Chandwani\(^1\). \(^1\)Weill Cornell Medicine, New York, NY, \(^2\)University of Michigan Medical School, Michigan, NY.

PO-084  The role of p53 in the development of pancreatic ductal adenocarcinoma. Kathryn J. Hanson, Brittany M. Flowers, Nicholas Hughes, Hannes Vogel, Le Cong, Laura D. Attardi. Stanford University, Stanford, CA.

PO-085  Identification of the nucleotide-free state as a therapeutic vulnerability for mutant selective inhibition of RAS. Imran Khan\(^1\), Akiko Koide\(^2\), Mariyam Zuberi\(^1\), Gayatri Ketavarapu\(^2\), Eric Denbaum\(^2\), Kai Wen Teng\(^2\), Matthew Rhett\(^1\), Russell Spencer Smith\(^3\), G. Aaron Hobbs\(^1\), Ernest Ramsay Camp\(^1\), Shohei Koide\(^2\), John P. O' Bryan\(^1\). \(^1\)Medical University of South Carolina, Charleston, SC, \(^2\)New York University, New York, NY, \(^3\)University of Illinois Chicago, Chicago, IL.


PO-087  SCAP-SREBP signaling is essential for acinar cell differentiation and maintenance, and pancreatic morphogenesis, influencing resident pools of cancer-forming progenitor cells. Anna C. Lilly, Aizhan Surumbayeva, Erica A Golemis, Igor Atsaturov. Fox Chase Cancer Center, Philadelphia, PA.

PO-088  Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer. Sauyeun Shin\(^1\), Remy Nicolle\(^2\), Mehdi Liauzun\(^1\), Jacobo Solorzano\(^1\), Alexia Brunel\(^1\), Christine Jean\(^1\), Remi Samain\(^1\), Jerôme Raffenne\(^1\), Cindy Neuzillet\(^4\), Carine Joffré\(^4\), Stephane Rocci\(^5\), Juan Iovanna\(^6\), Nelson Dusetti\(^6\), Ola Larsson\(^7\), Stephane Pyronnet\(^1\), Corinne Bousquet\(^1\), Yvan Martinneau\(^1\). \(^1\)CRCT, Inserm U1037, Toulouse, France, \(^2\)CIT, Ligue Nationale Contre Le Cancer, Paris, France, \(^3\)Medical Oncology Department, Curie Institute, Saint Cloud, France, \(^4\)CRCT Inserm U1037, Toulouse, France, \(^5\)C3M, Inserm U1065, Nice, France, \(^6\)CRCM, Inserm, Marseille, France, \(^7\)Karolinska Institutet, Stockholm, Sweden.

PO-089  Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. Shruthi Narayanan\(^1\), Oihane Erice\(^2\), Iker Feliu\(^2\), Caterina Vicentina\(^3\), Rodrigo Entrialgo-Cadierno\(^2\), Karmeke Valencia\(^2\), Elisabet Guruceaga\(^4\), Purvesh Khatri\(^5\), Vicenzo Corbo\(^3\), Silvestre Vicent Cambra\(^6\), Mariano Ponz-Sarvise\(^1\). \(^1\)Clinica Universidad de Navarra, Medical Oncology Department, Pamplona, Spain, \(^2\)University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain, \(^3\)Department of Diagnostics and Public Health, University of Verona, Verona, Italy, \(^4\)University of Navarra, Center for Applied Medical Research, Computational Biology Program, Pamplona, Spain, \(^5\)Stanford University, Stanford, CA, \(^6\)University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Department of Pathology, Anatomy and Physiology;
IdiSNA, Navarra Institute for Health Research; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Pamplona, Spain.

PO-090  TGF-β induced EMT gene expression is associated with promoter demethylation in pancreatic cancer. Manjul Rana¹, Abul Elahi¹, Abidemi O. Ajidahun¹, Rita G. Kansal¹, Anders E. Berglund², David Shibata¹, Evan S. Glazer¹. ¹UTHSC, Memphis, TN, ²Moffitt Cancer Center, Tampa, FL.

PO-091  Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors. Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. ¹UCSD, La Jolla, CA.

PO-092  Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells. Jingwei Shi, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-093  JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1. Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-094  Ga13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition. Mario A. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, Hidayatullah G. Munshi. Northwestern University, Chicago, IL.

Tumor Microenvironment

PO-095  A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Jaime Abrego¹, Hannah Sanford-Crane¹, Chet Oon¹, Xu Xiao², Courtney Betts¹, Duanchen Sun³, Shanthi Nagarajan¹, Zheng Xia³, Lisa Coussens¹, Peter Tontonoz³, Mara Sherman¹. ¹Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, ³Computational Biology Program, Oregon Health & Science University, Portland, OR, ⁴Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, ⁵Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PO-096  The synaptic protein Netrin G1 ligand (NGL-1) modulates tumorigenesis and immunosuppression in pancreatic cancer. Debora Barbosa Vendramini Costa¹, Ralph Francescone¹, Janusz Franco-Barraza¹, Tiffany Luong¹, Nina Steele², Benjamin Allen², Marina Pasca di Magliano³, Charline Ogier¹, Igor Astsaturov¹, Kathy Q Cai¹, Andres J Klein-Szanto¹, Huamin Wang⁴, Kerry Campbell¹, Edna Cukierman¹. ¹Fox Chase Cancer Center, Philadelphia, PA, ²Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, ³Department of Surgery, University of Michigan, Ann Arbor, MI, ⁴Department of Anatomical
Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

PO-097  Addition of losartan to FOLFORINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. Yves Boucher1, Jessica M. Posada2, Sonu Subudhi2, Ashwin S. Kumar2, Ivy X. Chen2, Mei R. Ng2, Mari Mino-Kenudson3, Nilesh Talele2, Dan G. Duda2, Dai Fukumura3, Janet E. Murphy3, Jeffrey W. Clark3, David P. Ryan3, Carlos Fernandez-Del Castillo3, Theodore S. Hong3, Rakesh K. Jain3. 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA.

PO-098  Longitudinal profiling of pancreatic cancer patients identifies interleukin-8 as a mediator of myeloid-epithelial crosstalk. Eileen S. Carpenter1, Samantha Kemp1, Padma Kadiyala1, Nina Steele1, Ahmed Elhossiny1, Stephanie The1, Valerie Gunchick1, Rémy Nicolle3, Michelle Anderson1, Wenting Du1, Carlos Espinoza1, Richard Kwon1, Erik-Jan Wamsteker1, Anoop Prabhu1, Allison Schulman1, Vaibhav Sahai1, Timothy Frankel1, Filip Bednar1, Marina Pasca di Magliano1. 1University of Michigan, Ann Arbor, MI, 2University of Pennsylvania, Philadelphia, PA, 3Tumour Identity Card Program (CIT), French League Against Cancer, Paris, France.

PO-099  The immunogenic and therapeutic implications of cancer cell-mediated CD73 activity and extracellular adenosine signaling promote an immunosuppressive microenvironment in pancreatic cancer. Anna M. Chiarella1, Jason R. Pitaressi2, Kensuke Suzuki1, Alina Li1, Ting Chen1, Benjamin Izar1, Catherine S. Spina1, Gulam A. Manji1, Gizem Efe1. 1Columbia University Irving Medical Center, New York City, NY, 2University of Pennsylvania, Philadelphia, PA.

PO-100  Lorazepam promotes desmoplasia and ischemic necrosis in murine pancreatic ductal adenocarcinoma. Abigail C. Cornwell, Abdulrahman A. Alahmari, Arwen A. Tisdale, Kathryn Maraszek, Swati Venkat, Michael E. Feigin. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-101  Characterization of longitudinally collected fine needle aspiration biopsies of pancreatic ductal adenocarcinoma upon endoscopic ultrasound guided radiofrequency ablation. Krisha Desai1, Patrick Varun Lawrence1, Christopher Wadsworth2, Nagina Mangal2, Nagy Habib2, Anguraj Sadanandam1, Mikael Sodergren2. 1Institute of Cancer Research, London, United Kingdom, 2Imperial College, London, United Kingdom.

PO-102  Fibroblast-derived interleukin-33 promotes pancreatic ductal adenocarcinoma as a result of tumor cell KRAS\textsuperscript{G12D}. Katelyn Donahue, Wenting Du, Carlos Espinoza, Eileen Carpenter, Kristee Brown, Nina Steele, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-103  Cellular origin influences immune microenvironment in a pancreatic cancer mouse model with loss of Pten and activation of Kras. Yan Dou1, Wesley Hunt1, Justin
PO-104  Activation of WNT signaling in CD4+ T cells promotes immune suppression in pancreatic cancer. Wenting Du, Rosa E. Menjivar, Katelyn Donahue, Ashley Velez-Delgado, Marina Pasca di Magliiano. University of Michigan, Ann Arbor, MI.

PO-105  Overcoming stromal barriers in PDA with a novel polymeric Toll-like receptor agonist. Christopher C. DuFort¹, Ciana L. Lopez², Martin C. Whittle¹, Vladimir Vlaskin², Aditi Vadodkar¹, Selvi Srinivasan², Patrick S. Stayton², Sunil R. Hingorani¹. ¹Fred Hutchinson Cancer Research Center, Seattle, WA, ²University of Washington, Seattle, WA.

PO-106  The extrinsic and modulatory effects of CSF-1/CSF-1R signaling in generating an immunosuppressive pancreatic cancer tumor microenvironment and promoting metastasis. Gizem Efe¹, Kensuke Suzuki¹, Jason R. Pitarresi², Anna M. Chiarella¹, Alina L. Li¹, Anil K. Rustgi¹. ¹Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, ²University of Pennsylvania, Philadelphia, PA.

PO-107  Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer Barbara T. Grünwald¹, Curtis McCloskey¹, Antoine Devisme², Foram Vyas¹, Geoffroy Andrieux², Kazeera Aliar¹, Faizy Notta³, Grainne O’Kane¹, Julie Wilson³, Jennifer Knox¹, Sandra Fischer⁴, Thomas Kislinger¹, Melanie Boerries², Steven Gallinger³, Rama Khokha⁵. ¹Princess Margaret Cancer Centre, Toronto, ON, Canada, ²University of Freiburg, Freiburg, Germany, ³Ontario Institute for Cancer Research, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Princess Margaret Cancer Centre, Toronto, Canada.

PO-108  Evaluation of antitumor activity of modified-gemcitabine solid-lipid nanoparticle in pancreatic pdx models. Edward Agyare¹, Taylor Smith², Andriana Inkoom¹, Bo Han³, Jose Trevino⁴, Nkafu Bechem Ndemazy¹. ¹College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, ²Food and Drug Administration, Silver Spring, MD, ³Keck School of Medicine, University of Southern California, Los Angeles, CA, ⁴Department of Surgery, College of Medicine, Virginia Commonwealth University, Richmond, VA.

PO-109  Dynamic regulation of the expression of KRAS and its effectors determines the ability of pancreatic acinar cells to initiate tumorigenesis. Patrick Jacquemin, Mohamad Assi. University of Louvain, Brussels, Belgium.

PO-110  Targeting Cathepsin B in the pancreatic stellate cells stimulates CD8+ T cell dependent anti-tumor immune response. Bharti Garg, Tejeshwar Jain, Utpreksha Vaish, Vikas Dudeja. University of Alabama at Birmingham, birmingham, AL.

PO-112  Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Varintra E. Lander, Jad I. Belle, Brett L. Knolhoff, John M. Herndon, Cedric Mpoy, Buck E. Rogers, Julie K. Schwarz, David G. DeNardo. Washington University in St. Louis, St. Louis, MO.

PO-113  The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer. Ellen M. Langer1, Isabel A English1, Vidhi Shah1, Kevin MacPherson1, Kayleigh M. Kresse1, Brittany L. Allen-Petersen2, Colin J. Daniel1, Mara H. Sherman1, Andrew Adey1, Rosalie C. Sears1. 1Oregon Health & Science University, Portland, OR, 2Purdue University, West Lafayette, IN.

PO-114  STAT3 in cancer-associated fibroblasts promotes an immunosuppressive tumor microenvironment. Julia E. Lefler, Michael Ostrowski, Catherine MarElia-Bennett. Medical University of South Carolina (MUSC), Charleston, SC.

PO-115  Effects of mesothelin exerton tumor microenvironment in pancreatic ductal adenocarcinoma. Dongliang Liu1, Ethan Poteet, Zhengdong Liang, Emily Laplante, Lisa Brubaker, Sadhna Dhillgra, Aleksandar Milosavljevic, Changyi Chen, Qizhi Cathy Yao. Baylor College of Medicine, Houston, TX.

PO-116  Deletion of Arginase 1 in myeloid cells alters the pancreatic cancer microenvironment. Rosa E. Menjivar1, Zeribe Nwosu1, Wenting Du1, Katelyn Donahue1, Carlos Espinoza1, Ashley Velez-Delgado1, Kristee Brown1, Wei Yan1, Christopher Halbrook2, Yaqing Zhang1, Costas Lyssiotis1, Marina Pasca di Magliano1. 1University of Michigan, Ann Arbor, MI, 2University of California Irvine, Irvine, CA.

PO-117  The role of Hippo signaling in stromal-epithelial interactions in acinar-to-ductal metaplasia and pancreatic cancer initiation. Julia Messina-Pacheco1, Yasser Riazalhosseini2, Zu-hua Gao1, Alex Gregorieff1. 1Department of Pathology, McGill University and the Research Institute of McGill University Health Centre, Montreal, QC, Canada, 2Department of Human Genetics, McGill University and the McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada.

PO-118  The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. Hosein M. Aziz, Lawlaw Saida, Willem de Koning, Andrew Stubbs, Yunlei Li, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-119  DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer
cancer is associated with modulating immune suppression in the tumor microenvironment. Sai Preethi Nakkina\textsuperscript{1}, Sarah B. Gitto\textsuperscript{2}, Veethika Pandey\textsuperscript{2}, Jordan M. Beardsley\textsuperscript{1}, Michael W. Rohr\textsuperscript{1}, Jignesh G. Parikh\textsuperscript{3}, Otto Phanstiel\textsuperscript{4}, Deborah A. Altomare\textsuperscript{1}. \textsuperscript{1}University of Central Florida, Orlando, FL, \textsuperscript{2}University of Pennsylvania, Philadelphia, PA, \textsuperscript{3}Orlando VA Medical Center, Orlando, FL, \textsuperscript{4}College of Medicine, University of Central Florida, Orlando, FL.

PO-120 Differential expression of polyamine pathways in human pancreatic tumor progression and effects of polyamine blockade therapy on the \textit{in vivo} pancreatic tumor microenvironment. Sai Preethi Nakkina\textsuperscript{1}, Sarah B. Gitto\textsuperscript{2}, Veethika Pandey\textsuperscript{2}, Jignesh G. Parikh\textsuperscript{3}, Dirk Geerts\textsuperscript{4}, Kenneth P. Olive\textsuperscript{5}, Otto Phanstiel\textsuperscript{6}, Deborah A. Altomare\textsuperscript{1}, Carlo Maurer\textsuperscript{7}. \textsuperscript{1}University of Central Florida, Orlando, FL, \textsuperscript{2}University of Pennsylvania, Philadelphia, PA, \textsuperscript{3}Orlando VA Medical Center, Orlando, FL, \textsuperscript{4}University of Amsterdam, Amsterdam, Netherlands, \textsuperscript{5}Columbia University Medical Center, New York, NY, \textsuperscript{6}College of Medicine, Orlando, FL, \textsuperscript{7}Klinikum rechts der Isar der TU München, Munchen, Germany.

PO-121 Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. Bernat Navarro-Serer, Kenna Sherman, Laura D. Wood. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-122 Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer. Brian M. Olson, Alison J. Thomas, Michael B. Ware, Gregory B. Lesinski. Emory University, Atlanta, GA.

PO-123 Development of a 3D Biomimetic Metastatic Liver Niche Model for Pancreatic Cancer. Mahsa Pahlavan\textsuperscript{1}, Weikun Xiao\textsuperscript{2}, Flora Eun\textsuperscript{3}, Chang-II Hwang\textsuperscript{3}, Reginald Hill\textsuperscript{2}. \textsuperscript{1}Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, \textsuperscript{2}Lawrence J. Ellison Institute for Translational Medicine of USC, University of Southern California, Los Angeles, CA, \textsuperscript{3}Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California Davis, Davis, CA.

PO-124 EZH2 blockade overcomes suppression of the proinflammatory senescence-associated secretory phenotype in the pancreas and drives NK cell-mediated pancreatic tumor responses. Loretah Chibaya\textsuperscript{1}, Yvette Lopez-Diaz\textsuperscript{1}, Haibo Liu\textsuperscript{1}, Katherine C Murphy\textsuperscript{1}, John P. Morris IV\textsuperscript{2}, Yu-jui Ho\textsuperscript{2}, Janelle Simon\textsuperscript{2}, Wei Luan\textsuperscript{2}, Amanda Kulick\textsuperscript{2}, Lakhena Leang\textsuperscript{1}, Elisa de Stanchina\textsuperscript{2}, Lihua J. Zhu\textsuperscript{1}, Scott W. Lowe\textsuperscript{2}, Marcus Ruscetti\textsuperscript{1}. \textsuperscript{1}University of Massachusetts Medical School, Worcester, MA, \textsuperscript{2}Memorial Sloan Kettering Cancer Center, New York, NY.

PO-125 The role of KDM6A in pancreatic cancer immune microenvironment. Lin Jin, Jing Yang, Zhujun Yi, Hong S Kim, Feng Tian, Jiaqi Shi. University of Michigan, Ann Arbor, MI.

PO-126 Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma. Kevin J. Tu\textsuperscript{1}, Sanjit K. Roy\textsuperscript{1}, Binny Bhandary\textsuperscript{2}, Amit Sawant\textsuperscript{1}, Hem D. Shukla\textsuperscript{1}. \textsuperscript{1}University of Maryland School of Medicine, Baltimore, MD, \textsuperscript{2}University of Maryland,
PO-127  A uPA/uPAR axis in both the tumor cell and stromal compartment drives PDAC disease progression. Yi Yang, Sara R. Abrahams, Aditi Kothari, Harshi Matada, Keely Davey, Alisa S. Wolberg, Matthew J. Flick. University of North Carolina, Chapel Hill, Chapel Hill, NC.

PO-128  Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. Salina Yuan¹, Jinyang Li², Ben Stanger¹, Robert Norgard³, Fangxue Yan¹, Il-Kyu Kim¹, Allyson Merrell⁴, Yohev Sela¹, Yanqing Jiang¹, Natarajan V. Bhanu¹, Ben A. Garcia¹, Robert H. Vonderheide⁵, Andres Blanco⁶, Yu H. Sun⁷. ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Rockefeller University, New York City, NY, ³Boehringer Ingelheim, Ridgefield, CT, ⁴Ambys Medicines, San Francisco, CA, ⁵Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, ⁶School of Veterinary Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷University of Rochester Medical Center, Rochester, NY.


PO-130  Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment. Yijuan Zhang¹, M. Victoria Recouvreux¹, Michael Jung¹, Koen Galencamp¹, Yunbo Li², Olga Zagnitko¹, David Scott¹, Andrew Lowy², Cosimo Commisso¹. ¹Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, ²University of California San Diego, La Jolla, CA.

PO-131  The role of liver endothelium on pancreatic cancer growth. Wei Zhang¹, Michel’le Wright¹, Moeez Rathore¹, Ali Vaziri-Gohar¹, Jordan Winter², Rui Wang². ¹Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH.